Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 3/20 | 0.39 |
| ▸ | MMP3 | P08254 | 3/20 | 0.39 |
| ▸ | MMP7 | P09237 | 3/20 | 0.39 |
| ▸ | MMP9 | P14780 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037128 | 0.93 | CTSK (0.54) | CTSKCTSSMMP1MMP3MMP9 | |
| SCHEMBL4042964 | 0.92 | CTSK (0.49) | CTSKKCNQ1CTSSHSD17B10ALDH1A1 | |
| SCHEMBL4042400 | 0.92 | LMNA (0.43) | CTSKKCNQ1LMNACHRNB4CHRNA3 | |
| SCHEMBL4041749 | 0.92 | CTSK (0.53) | CTSKLMNACTSSHSD17B10POLB | |
| SCHEMBL4039854 | 0.91 | CTSK (0.51) | CTSKLMNACTSSHSD17B10POLB | |
| SCHEMBL4042094 | 0.91 | CTSK (0.53) | CTSKCTSSHSD17B10POLBKMT2A | |
| SCHEMBL4040525 | 0.91 | CTSK (0.53) | CTSKCTSSHSD17B10POLBKMT2A | |
| SCHEMBL4039791 | 0.90 | CTSK (0.64) | CTSKLMNACTSSHSD17B10ALDH1A1 | |
| SCHEMBL4040176 | 0.90 | CTSK (0.52) | CTSKLMNACHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4043892 | 0.90 | CTSK (0.51) | CTSKCTSSHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558603-A4 | OXYGE-CONTAINING HETEROCYCLIC FUSED NAPHTHOPYRANS | INSIGHT EQUITY A P X LP (US) | 2009-03-18 | — | — | EP | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1558603-A2 | OXYGE-CONTAINING HETEROCYCLIC FUSED NAPHTHOPYRANS | Vision-Ease Lens, Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| WO-2004047674-A2 | OXYGE-CONTAINING HETEROCYCLIC FUSED NAPHTHOPYRANS | VISION-EASE LENS, INC. (US) | 2004-06-10 | — | — | WO | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885KCNQ1 3181/4885LMNA 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.